Legal & General Group Plc Buys 1,261 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Legal & General Group Plc raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 69,425 shares of the company’s stock after acquiring an additional 1,261 shares during the period. Legal & General Group Plc’s holdings in Krystal Biotech were worth $10,876,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. US Bancorp DE grew its holdings in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after buying an additional 121 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after buying an additional 121 shares in the last quarter. Perigon Wealth Management LLC boosted its position in shares of Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after acquiring an additional 123 shares in the last quarter. Finally, Xponance Inc. increased its stake in Krystal Biotech by 9.5% in the fourth quarter. Xponance Inc. now owns 1,785 shares of the company’s stock valued at $280,000 after acquiring an additional 155 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on KRYS shares. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. Chardan Capital lifted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average price target of $220.00.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Trading Down 2.6 %

Shares of KRYS opened at $164.70 on Thursday. The stock has a market cap of $4.76 billion, a P/E ratio of 55.08 and a beta of 0.75. The stock’s 50-day moving average price is $174.45 and its two-hundred day moving average price is $172.08. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.30 earnings per share. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).